Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02802228 · ClinicalTrials.gov registry record · Phase 2
Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients
A Phase 2 study, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT02802228 is a Phase 2 study that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT02802228, a Phase 2 study, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This placebo-controlled study will assess the safety and efficacy of a 90-day course of treatment with ifetroban for portal hypertension in cirrhotic patients
Interventions
- DRUG Placebo
- DRUG Ifetroban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-03-06 |
| Est. Completion | 2018-07-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02802228
The ClinicalTrials.gov registry entry for NCT02802228 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02802228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02802228 about?
NCT02802228 is a clinical study titled "Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients". This placebo-controlled study will assess the safety and efficacy of a 90-day course of treatment with ifetroban for portal hypertension in cirrhotic patients
What is the current status of trial NCT02802228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2017-03-06. Estimated completion is 2018-07-17.
What interventions are being tested in trial NCT02802228?
The interventions under investigation include: Placebo (DRUG), Ifetroban (DRUG).
Who is sponsoring clinical trial NCT02802228?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.